Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma


To determine if the acute toxicity of an autologous stem cell transplant with a busulfan/ melphalan (BuMel) based regimen is tolerable when given as Consolidation therapy for high-risk neuroblastoma.


autologous, stem cell transplant, consolidation therapy, neuroblastoma, high-risk

Principal Investigator

William Slayton, M.D.



Contact Information


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at CTSI-Studies-L@lists.ufl.edu.

Other Resources

  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams